ASP Isotopes (NASDAQ:ASPI) CEO Paul Elliot Mann Sells 81,076 Shares

Key Points

• ASP Isotopes CEO Paul Elliot Mann sold 81,076 shares for $691,578.28, reducing his stake by 1.11% but still holds over 7 million shares valued at approximately $61.7 million.
• The company's stock is currently down 1.5%, trading at $8.37, with a year low of $2.32 and a year high of $11.68.
• ASP Isotopes recently reported a quarterly loss of ($1.03) earnings per share, significantly missing analyst expectations, and had revenue of $1.20 million compared to a forecast of $1.60 million.

ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) CEO Paul Elliot Mann sold 81,076 shares of the company's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $8.53, for a total transaction of $691,578.28. Following the completion of the transaction, the chief executive officer owned 7,234,378 shares of the company's stock, valued at approximately $61,709,244.34. This trade represents a 1.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Paul Elliot Mann also recently made the following trade(s):

• On Tuesday, September 9th, Paul Elliot Mann sold 81,077 shares of ASP Isotopes stock. The shares were sold at an average price of $8.39, for a total value of $680,236.03.

ASP Isotopes Stock Down 1.9%

ASP Isotopes stock traded down $0.16 during midday trading on Monday, hitting $8.61. 1,550,161 shares of the stock were exchanged, compared to its average volume of 3,197,048. The stock has a market capitalization of $791.00 million, a price-to-earnings ratio of -14.14 and a beta of 3.35. The company has a quick ratio of 14.56, a current ratio of 14.72 and a debt-to-equity ratio of 3.53. ASP Isotopes Inc. has a 52-week low of $2.55 and a 52-week high of $11.68. The business's 50-day moving average price is $9.15 and its 200-day moving average price is $7.18.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($1.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.92). ASP Isotopes had a negative return on equity of 239.22% and a negative net margin of 2,181.62%.The firm had revenue of $1.20 million for the quarter, compared to the consensus estimate of $1.60 million. On average, research analysts expect that ASP Isotopes Inc. will post -0.24 EPS for the current fiscal year.

Institutional Trading of ASP Isotopes

Several large investors have recently made changes to their positions in the business. BNP Paribas Financial Markets purchased a new position in ASP Isotopes during the fourth quarter valued at $34,000. Ameritas Investment Partners Inc. grew its holdings in shares of ASP Isotopes by 41.2% in the second quarter. Ameritas Investment Partners Inc. now owns 5,483 shares of the company's stock valued at $40,000 after purchasing an additional 1,600 shares in the last quarter. SBI Securities Co. Ltd. grew its holdings in shares of ASP Isotopes by 84.8% in the first quarter. SBI Securities Co. Ltd. now owns 9,370 shares of the company's stock valued at $44,000 after purchasing an additional 4,299 shares in the last quarter. Millennium Management LLC purchased a new position in shares of ASP Isotopes in the 4th quarter valued at about $55,000. Finally, Fortitude Advisory Group L.L.C. acquired a new position in shares of ASP Isotopes in the 1st quarter valued at $64,000. 16.80% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group upped their target price on shares of ASP Isotopes from $8.50 to $11.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $7.75.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.